Cancer Epidemiology Biomarkers & Prevention, Vol 2, Issue 5 467-472, Copyright © 1993 by American Association for Cancer Research

ARTICLES

Vitamin D and prostate cancer: a prediagnostic study with stored sera

EH Corder, HA Guess, BS Hulka, GD Friedman, M Sadler, RT Vollmer, B Lobaugh, MK Drezner, JH Vogelman and N Orentreich
Department of Medicine, Duke University Medical Center, Durham, North Carolina.

This study evaluates the risk of prostate cancer in relation to serum levels of the major vitamin D metabolites, 25-hydroxyvitamin D (25-D3) and 1,25-dihydroxyvitamin D (1,25-D). Between 1964 and 1971, more than 250,000 serum samples were collected from members of the Kaiser Permanente Medical Care Plan in Oakland and San Francisco and stored for future use. Levels of 25-D and 1,25-D were measured in samples from 90 black and 91 white men diagnosed with prostate cancer before December 31, 1987 and controls individually matched on age, race, and day of serum storage. Mean serum 1,25-D was 1.81 pg/ml lower in cases than in matched controls (P = 0.002). Risk of prostate cancer decreased with higher levels of 1,25-D especially in men with low levels of 25-D. However, mean 25-D was not significantly different in cases and controls. The association of lower 1,25-D with prostate cancer was found in men above the median age of 57 years at serum storage but not younger men and was similar in black and white men. In men > or = 57 years of age, 1,25-D was an important predictor of risk for palpable and anaplastic tumors but not for tumors incidentally discovered during surgery to treat the symptoms of benign prostatic hyperplasia or well differentiated tumors.

This article has been cited by other articles:

				J. Ahn, U. Peters, D. Albanes, M. P. Purdue, C. C. Abnet, N. Chatterjee, R. L. Horst, B. W. Hollis, W.-Y. Huang, J. M. Shikany, et al. Serum Vitamin D Concentration and Prostate Cancer Risk: A Nested Case-Control Study J Natl Cancer Inst, June 4, 2008; 100(11): 796 - 804. [Abstract] [Full Text] [PDF]

				C. N. Holick, J. L. Stanford, E. M. Kwon, E. A. Ostrander, S. Nejentsev, and U. Peters Comprehensive Association Analysis of the Vitamin D Pathway Genes, VDR, CYP27B1, and CYP24A1, in Prostate Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1990 - 1999. [Abstract] [Full Text] [PDF]

				H.-J. Ting, B.-Y. Bao, J. E. Reeder, E. M. Messing, and Y.-F. Lee Increased Expression of Corepressors in Aggressive Androgen-Independent Prostate Cancer Cells Results in Loss of 1{alpha},25-Dihydroxyvitamin D3 Responsiveness Mol. Cancer Res., September 1, 2007; 5(9): 967 - 980. [Abstract] [Full Text] [PDF]

				P. Tuohimaa, L. Tenkanen, H. Syvala, S. Lumme, T. Hakulinen, J. Dillner, and M. Hakama Interaction of Factors Related to the Metabolic Syndrome and Vitamin D on Risk of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 302 - 307. [Abstract] [Full Text] [PDF]

				E. Giovannucci, Y. Liu, E. B. Rimm, B. W. Hollis, C. S. Fuchs, M. J. Stampfer, and W. C. Willett Prospective study of predictors of vitamin d status and cancer incidence and mortality in men. J Natl Cancer Inst, April 5, 2006; 98(7): 451 - 459. [Abstract] [Full Text] [PDF]

				E. Giovannucci, Y. Liu, M. J. Stampfer, and W. C. Willett A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 203 - 210. [Abstract] [Full Text] [PDF]

				C. F. Garland, F. C. Garland, E. D. Gorham, M. Lipkin, H. Newmark, S. B. Mohr, and M. F. Holick The Role of Vitamin D in Cancer Prevention Am J Public Health, February 1, 2006; 96(2): 252 - 261. [Abstract] [Full Text] [PDF]

				E. M. John, G. G. Schwartz, J. Koo, D. Van Den Berg, and S. A. Ingles Sun Exposure, Vitamin D Receptor Gene Polymorphisms, and Risk of Advanced Prostate Cancer Cancer Res., June 15, 2005; 65(12): 5470 - 5479. [Abstract] [Full Text] [PDF]

				J. A. Baron, M. Beach, K. Wallace, M. V. Grau, R. S. Sandler, J. S. Mandel, D. Heber, and E. R. Greenberg Risk of Prostate Cancer in a Randomized Clinical Trial of Calcium Supplementation Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 586 - 589. [Abstract] [Full Text] [PDF]

				A. Jemal, E. Ward, X. Wu, H. J. Martin, C. C. McLaughlin, and M. J. Thun Geographic Patterns of Prostate Cancer Mortality and Variations in Access to Medical Care in the United States Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 590 - 595. [Abstract] [Full Text] [PDF]

				M. F. McCarty Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380. [Abstract] [PDF]

				L. V. Stewart and N. L. Weigel Vitamin D and Prostate Cancer Experimental Biology and Medicine, April 1, 2004; 229(4): 277 - 284. [Abstract] [Full Text] [PDF]

				C. Ntais, A. Polycarpou, and J. P. A. Ioannidis Vitamin D Receptor Gene Polymorphisms and Risk of Prostate Cancer: A Meta-analysis Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1395 - 1402. [Abstract] [Full Text] [PDF]

				G. Liu, G. Wilding, M. J. Staab, D. Horvath, K. Miller, A. Dresen, D. Alberti, R. Arzoomanian, R. Chappell, and H. H. Bailey Phase II Study of 1{alpha}-Hydroxyvitamin D2 in the Treatment of Advanced Androgen-independent Prostate Cancer Clin. Cancer Res., September 15, 2003; 9(11): 4077 - 4083. [Abstract] [Full Text] [PDF]

				C. Rodriguez, M. L. McCullough, A. M. Mondul, E. J. Jacobs, D. Fakhrabadi-Shokoohi, E. L. Giovannucci, M. J. Thun, and E. E. Calle Calcium, Dairy Products, and Risk of Prostate Cancer in a Prospective Cohort of United States Men Cancer Epidemiol. Biomarkers Prev., July 1, 2003; 12(7): 597 - 603. [Abstract] [Full Text] [PDF]

				D. M. Peehl, A. V. Krishnan, and D. Feldman Pathways Mediating the Growth-Inhibitory Actions of Vitamin D in Prostate Cancer J. Nutr., July 1, 2003; 133(7): 2461S - 2469. [Abstract] [Full Text] [PDF]

				A. Rao, R. D. Woodruff, W. N. Wade, T. E. Kute, and S. D. Cramer Genistein and Vitamin D Synergistically Inhibit Human Prostatic Epithelial Cell Growth J. Nutr., October 1, 2002; 132(10): 3191 - 3194. [Abstract] [Full Text] [PDF]

				G. Liu, K. Oettel, G. Ripple, M. J. Staab, D. Horvath, D. Alberti, R. Arzoomanian, R. Marnocha, R. Bruskewitz, R. Mazess, et al. Phase I Trial of 1{alpha}-Hydroxyvitamin D2 in Patients with Hormone Refractory Prostate Cancer Clin. Cancer Res., September 1, 2002; 8(9): 2820 - 2827. [Abstract] [Full Text] [PDF]

				R. Vieth Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study Am. J. Clinical Nutrition, August 1, 2002; 76(2): 490 - 491. [Full Text]

				J. M Chan Reply to R Vieth Am. J. Clinical Nutrition, August 1, 2002; 76(2): 491 - 491. [Full Text]

				A. R. Kristal, J. H. Cohen, P. Qu, and J. L. Stanford Associations of Energy, Fat, Calcium, and Vitamin D with Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., August 1, 2002; 11(8): 719 - 725. [Abstract] [Full Text] [PDF]

				D M Freedman, M Dosemeci, and K McGlynn Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: a composite death certificate based case-control study Occup. Environ. Med., April 1, 2002; 59(4): 257 - 262. [Abstract] [Full Text] [PDF]

				J. M Chan, M. J Stampfer, J. Ma, P. H Gann, J M. Gaziano, and E. L Giovannucci Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study Am. J. Clinical Nutrition, October 1, 2001; 74(4): 549 - 554. [Abstract] [Full Text] [PDF]

				K. A. Moffatt, W. U. Johannes, T. E. Hedlund, and G. J. Miller Growth Inhibitory Effects of 1{alpha}, 25-Dihydroxyvitamin D3 Are Mediated by Increased Levels of p21 in the Prostatic Carcinoma Cell Line ALVA-31 Cancer Res., October 1, 2001; 61(19): 7122 - 7129. [Abstract] [Full Text] [PDF]

				E. A. Platz, E. B. Rimm, W. C. Willett, P. W. Kantoff, and E. Giovannucci Racial Variation in Prostate Cancer Incidence and in Hormonal System Markers Among Male Health Professionals J Natl Cancer Inst, December 20, 2000; 92(24): 2009 - 2017. [Abstract] [Full Text] [PDF]

				P. E. Hutchinson, J. E. Osborne, J. T. Lear, A. G. Smith, P. W. Bowers, P. N. Morris, P. W. Jones, C. York, R. C. Strange, and A. A. Fryer Vitamin D Receptor Polymorphisms Are Associated with Altered Prognosis in Patients with Malignant Melanoma Clin. Cancer Res., February 1, 2000; 6(2): 498 - 504. [Abstract] [Full Text]

				D. C. Smith, C. S. Johnson, C. C. Freeman, J. Muindi, J. W. Wilson, and D. L. Trump A Phase I Trial of Calcitriol (1,25-Dihydroxycholecalciferol) in Patients with Advanced Malignancy Clin. Cancer Res., June 1, 1999; 5(6): 1339 - 1345. [Abstract] [Full Text] [PDF]

				B. L. Lokeshwar, G. G. Schwartz, M. G. Selzer, K. L. Burnstein, S.-H. Zhuang, N. L. Block, and L. Binderup Inhibition of Prostate Cancer Metastasis in Vivo: A Comparison of 1,25-Dihydroxyvitamin D (Calcitriol) and EB1089 Cancer Epidemiol. Biomarkers Prev., March 1, 1999; 8(3): 241 - 248. [Abstract] [Full Text] [PDF]

				E. Ruijter, C. van de Kaa, G. Miller, D. Ruiter, F. Debruyne, and J. Schalken Molecular Genetics and Epidemiology of Prostate Carcinoma Endocr. Rev., February 1, 1999; 20(1): 22 - 45. [Abstract] [Full Text]

				L. Xue, M. Lipkin, H. Newmark, and J. Wang Influence of Dietary Calcium and Vitamin D on Diet-Induced Epithelial Cell Hyperproliferation in Mice J Natl Cancer Inst, January 20, 1999; 91(2): 176 - 181. [Abstract] [Full Text] [PDF]

				C. Lopez-Otin and E. P. Diamandis Breast and Prostate Cancer: An Analysis of Common Epidemiological, Genetic, and Biochemical Features Endocr. Rev., August 1, 1998; 19(4): 365 - 396. [Abstract] [Full Text] [PDF]

				F. Yeung, W. K. Law, C.-H. Yeh, J. J. Westendorf, Y. Zhang, R. Wang, C. Kao, and L. W. K. Chung Regulation of Human Osteocalcin Promoter in Hormone-independent Human Prostate Cancer Cells J. Biol. Chem., January 18, 2002; 277(4): 2468 - 2476. [Abstract] [Full Text] [PDF]